Prospective Study of Stereotactic Radiology Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Condition: Recurrent or Progressive Glioblastoma Interventions: Drug: Bevacizumab; Drug: Bevacizumab with chemo; Radiation: Fractionated radiosurgery Sponsor: Henry Ford Health System Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials